Gilead HIV drug not entitled to SPC, says UK court

The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate (SPC) because it failed to meet the standards set out by Europe’s highest court earlier this year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC hands Occlutech second win against Chinese medtech company in a month

19 June 2026 The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.

Europe

Exclusive: ‘Cultural differences are an asset’ at the UPC

16 June 2026 In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.

Europe

Siemens ordered to recall mammography device across European countries

11 June 2026 The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.

More features

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

UPC hands Occlutech second win against Chinese medtech company in a month

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Exclusive: ‘Cultural differences are an asset’ at the UPC

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Gilead HIV drug not entitled to SPC, says UK court

More on this story

Editor's picks

Editor's picks

More features